Home>>Signaling Pathways>> Others>>Ro18-5362

Ro18-5362

Catalog No.GC30746

Ro18-5362 is the less active prodrug of Ro 18-5364.

Products are for research use only. Not for human use. We do not sell to patients.

Ro18-5362 Chemical Structure

Cas No.: 101387-97-7

Size Price Stock Qty
1mg
$534.00
In stock
5mg
$1,057.00
In stock
10mg
$1,801.00
In stock
20mg
$3,171.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ro18-5362 is the less active prodrug of Ro 18-5364. Even at concentrations as high as 0.1 mM Ro 18-5362 fails to affect significantly (H++K+)-ATPase activity and associated proton translocation.

Marked differences are seen between Ro 18-5364 (sulfoxide) and Ro18-5362 (sulfide) with regard to inhibitory activity. Even at concentrations as high as 0.1 mM Ro18-5362 fails to affect significantly (H++K+)-ATPase activity and associated proton translocation[1]. The sulfoxide Ro 18-5364, a potential metabolite of the IND Ro18-5362, is a powerful inhibitor of gastric mucosal (H++K+)-ATPase, decreasing enzymatic activity with an apparent Ki of 0.1 μM[2].

[1]. Sigrist-Nelson K, et al. Ro 18-5364, a potent new inhibitor of the gastric (H+ + K+)-ATPase. Eur J Biochem. 1987 Jul 15;166(2):453-9. [2]. Sigrist-Nelson K, et al. Gastric (H+ + K+)-ATPase: modulation of the inhibitory properties of the novel potent antisecretagogue Ro 18-5364 by sulfhydryl reagents and nucleotides. FEBS Lett. 1986 Mar 3;197(1-2):187-91.

Reviews

Review for Ro18-5362

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ro18-5362

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.